The Inventor of Ozempic Is Suddenly Sacking Huge Numbers of Employees
Novo Nordisk will cut about 11% of its workforce (roughly 9,000 employees) to save $1.3 billion amid shrinking GLP-1 market share and intensified competition.
Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma's Path to Dominance
Novo Nordisk regained momentum in the GLP-1 market after competition and shortages, driven by strategic wins, resolved shortages, and expanded drug indications, boosting its stock.
